Claims for Patent: 9,566,259

Summary for Patent: 9,566,259

Title:	Fumarate ester dosage forms
Abstract:	Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One embodiment described herein is a pharmaceutical composition comprising fumarate esters suspended in a lipid or lipophilic liquid with enhanced bioavailability.
Inventor(s):	Vaughn; Jason M. (Browns Summit, NC), Hughey; Justin R. (Asheboro, NC), Roberts; Tanesha (Greensboro, NC), Dyakonov; Tatyana (Greensboro, NC), Agnihotri; Sunil (Scarborough, ME), Fatmi; Aqeel A. (High Point, NC)
Assignee:	BANNER LIFE SCIENCES LLC (High Point, NC)
Application Number:	15/299,535
Patent Claims:	1. An oral immediate release pharmaceutical composition comprising a single-phase non-aqueous liquid comprising dimethyl fumarate, monomethyl fumarate, a pro-drug of monomethyl fumarate, or a combination thereof. 2. The composition of claim 1, wherein the composition comprises about 90 mg to about 110 mg or about 180 mg to about 220 mg of the fumarate ester. 3. The composition of claim 1, wherein the single-phase non-aqueous liquid comprises a lipid liquid or lipophilic liquid. 4. The composition of claim 1, wherein the liquid comprises mono- and di-glycerides, polyvinylpyrrolidone, polyoxyl 40 hydrogenated castor oil, and lactic acid. 5. The composition of claim 1, wherein the fumarate ester to liquid weight ratio is from about 1:1 to about 1:8. 6. The composition of claim 1, wherein the fumarate ester to liquid weight ratio is about 1:2. 7. The composition of claim 1, wherein the fumarate ester comprises about 10% to about 50%, about 20% to about 40%, or about 30% to about 40% of the composition by weight. 8. The composition of claim 1, wherein the liquid comprises about 50% to about 85% or about 60% to about 70% of the composition by weight. 9. The composition of claim 1, wherein the composition comprises: about 30% to about 40% by weight of the one or more fumarate esters; about 55% to about 65% by weight of the liquid; and about 5% by weight of lactic acid. 10. The composition of claim 1, wherein the composition is encapsulated in a capsule, soft capsule, or enteric soft capsule. 11. The composition of claim 1, wherein the composition is encapsulated in an enterically coated soft capsule. 12. The composition of claim 11, wherein the enterically coated capsule provides delayed release of the fumarate ester. 13. The composition of claim 1, wherein the fumarate ester is dimethyl fumarate. 14. The composition of claim 1, wherein the fumarate ester is monomethyl fumarate. 15. The composition of claim 1, wherein upon administration to a subject, the composition activates a nuclear factor erythroid-derived 2-like (Nrf2) dependent pathway. 16. An oral pharmaceutical composition comprising: about 12% to about 40% by weight of one or more fumarate esters; about 50% to about 80% by weight of mono- and di-glycerides; about 5% to about 15% by weight of polyoxyl 40 hydrogenated castor oil; about 1% to about 5% by weight of polyvinylpyrrolidone; and about 1% to about 5% by weight lactic acid. 17. The composition of claim 16, wherein the composition comprises about 80 mg to about 110 mg or about 160 mg to about 230 mg of the fumarate ester. 18. The composition of claim 16, wherein the fumarate ester is dimethyl fumarate. 19. The composition of claim 16, wherein the fumarate ester is monomethyl fumarate. 20. The composition of claim 16, wherein the composition is encapsulated in an enterically coated soft capsule. 21. The composition of claim 20, wherein the composition exhibits an in vitro dissolution rate comprising about 50% dissolution after about 30 minutes at pH 6.8. 22. An oral immediate release pharmaceutical composition comprising a single-phase non-aqueous liquid suspension of about 90 mg to about 220 mg of one or more fumarate esters that upon administration to a subject is bioequivalent to a 240 mg dose of dimethyl fumarate. 23. The composition of claim 22, wherein the fumarate ester comprises is dimethyl fumarate, monomethyl fumarate, or a combination thereof. 24. The composition of claim 22, wherein administration comprises: (a) administering two doses simultaneously comprising about 90 mg to about 110 mg of fumarate ester twice per day (BID); (b) administering one dose comprising about 90 mg to about 110 mg of fumarate ester four times per day (QID); or (c) administering one dose comprising about 180 to about 220 mg of fumarate ester twice per day (BID). 25. The composition of claim 22, wherein upon administration to a subject, the composition activates a nuclear factor erythroid-derived 2-like (Nrf2) dependent pathway. 26. A method for manufacturing an oral pharmaceutical dosage form comprising a fumarate ester, the method comprising: (a) combining lactic acid with a single phase non aqueous liquid and mixing; (b) introducing one or more fumarate esters into the mixed liquid and homogenizing; (c) preparing a gel mass comprising a film-forming, water-soluble polymer, an appropriate plasticizer, and solvent; (d) casting the gel mass into films or ribbons using heat-controlled drums or surfaces; and (e) encapsulating the homogenized solution (b) within the gel mass films or ribbons using rotary dye encapsulation, forming capsules. 27. The method of claim 26 further comprising: (f) coating the capsules of (e) with an enteric coating. 28. An oral pharmaceutical dosage form comprising one or more fumarate esters produced by the method of claim 26. 29. The dosage form of claim 28, wherein the fumarate ester comprises dimethyl fumarate, monomethyl fumarate, or a combination thereof.